journal article·2024-06Open access

Application of Doxorubicin-loaded PLGA nanoparticles targeting both tumor cells and cancer-associated fibroblasts on 3D human skin equivalents mimicking melanoma and cutaneous squamous cell carcinoma

Yuanyuan He, Shidi Wu, Marion Rietveld, Maarten Vermeer, Luis J. Cruz, Christina Eich, Abdoelwaheb El Ghalbzouri

Abstract

Nanoparticle (NP) use in cancer therapy is extensively studied in skin cancers. Cancer-associated fibroblasts (CAFs), a major tumor microenvironment (TME) component, promote cancer progression, making dual targeting of cancer cells and CAFs an effective therapy. However, dual NP-based targeting therapy on both tumor cells and CAFs is poorly investigated in skin cancers. Herein, we prepared and characterized doxorubicin-loaded PLGA NPs (DOX@PLGA NPs) and studied their anti-tumor effects on cutaneous melanoma (SKCM)(AN, M14) and cutaneous squamous cell carcinoma (cSCC) (MET1, MET2) cell lines in monolayer, as well as their impact on CAF deactivation. Then, we established 3D full thickness models (FTM) models of SKCM and cSCC using AN or MET2 cells on dermis matrix populated with CAFs respectively, and assessed the NPs' tumor penetration, tumor-killing ability, and CAF phenotype regulation through both topical administration and intradermal injection. The results show that, in monolayer, DOX@PLGA NPs inhibited cancer cell growth and induced apoptosis in a dose- and time-dependent manner, with a weaker effect on CAFs. DOX@PLGA NPs reduced CAF-marker expression and had successful anti-tumor effects in 3D skin cancer FTMs, with decreased tumor-load and invasion. DOX@PLGA NPs also showed great delivery potential in the FTMs and could be used as a platform for future functional study of NPs in skin cancers using human-derived skin equivalents. This study provides promising evidence for the potential of DOX@PLGA NPs in dual targeting therapy for SKCM and cSCC.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Cancer Cells and Metastasis · Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (64)

Show source-provided references
1. Skin cancer: primary, secondary, and tertiary prevention10.1016/j.jaad.2021.12.066 ↗
2. Cutaneous squamous cell carcinoma: incidence, risk factors, diagnosis, and staging10.1016/j.jaad.2017.08.059 ↗
3. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives10.1186/s12943-021-01428-1 ↗
4. Cancer-associated fibroblasts in mycosis fungoides promote tumor cell migration and drug resistance through CXCL12/CXCR410.1016/j.jid.2020.06.034 ↗
5. Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling10.1016/j.ccell.2015.03.008 ↗
6. Targeting CAFs to overcome anticancer therapeutic resistance10.1016/j.trecan.2022.03.001 ↗
7. Polymeric nanoparticles for drug delivery: recent developments and future prospects10.3390/nano10071403 ↗
8. Physicochemical properties and applications of poly(lactic-co-glycolic acid) for use in bone regeneration10.1089/ten.teb.2012.0443 ↗
9. PLGA-based nanomedicines manufacturing: technologies overview and challenges in industrial scale-up10.1016/j.ijpharm.2021.120807 ↗
10. Structure-based varieties of polymeric nanocarriers and influences of their physicochemical properties on drug delivery profiles
11. PLGA-based nanoparticles in cancer treatment10.3389/fphar.2018.01260 ↗
12. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death10.1136/jitc-2019-000337 ↗
13. Comparison of human skin or epidermis models with human and animal skin in in-vitro percutaneous absorption10.1016/S0378-5173(00)00665-7 ↗
14. In vitro skin permeation evaluation: the only realistic option10.1046/j.1467-2494.1998.181622.x ↗
15. Human skin equivalents: impaired barrier function in relation to the lipid and protein properties of the stratum corneum10.1016/j.addr.2021.05.012 ↗
16. Doxorubicin-loaded PLGA nanoparticles for the chemotherapy of glioblastoma: towards the pharmaceutical development10.1016/j.ijpharm.2019.118733 ↗
17. PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer10.1038/s41598-018-25930-7 ↗
18. Doxorubicin loaded PLGA nanoparticle with cationic/anionic polyelectrolyte decoration: characterization, and its therapeutic potency10.3390/polym13050693 ↗
19. Anticancer activity of nanoparticles based on PLGA and its co-polymer: invitro evaluation
20. PLGA-nanoparticles for intracellular delivery of the CRISPR-complex to elevate fetal globin expression in erythroid cells10.1016/j.biomaterials.2020.120580 ↗
21. Ahmed, M.M.; Fatima, F.; Anwer, M.K.; Aldawsari, M.F.; Bhatia, S.; Al-Harrasi, A. Brigatinib loaded poly(d,l-lactide-co-glycolide) nanoparticles for improved anti-tumoral activity against non-small cell lung cancer cell lines. Drug Dev. Ind. Pharm. 2021, 47, 1112–1120, doi:https://doi.org/10.1080/03639045.2021.1983585.10.1080/03639045.2021.1983585 ↗
22. Nanoparticle colloidal stability in cell culture media and impact on cellular interactions10.1039/C4CS00487F ↗
23. pH-responsive high stability polymeric nanoparticles for targeted delivery of anticancer therapeutics10.1038/s42003-020-0817-4 ↗
24. Resveratrol-loaded PLGA nanoparticles: enhanced stability, solubility and bioactivity of resveratrol for non-alcoholic fatty liver disease therapy10.1098/rsos.181457 ↗
25. BCL-2 proteins and apoptosis: recent insights and unknowns10.1016/j.bbrc.2017.06.190 ↗
26. COL11A1 activates cancer-associated fibroblasts by modulating TGF-β3 through the NF-κB/IGFBP2 axis in ovarian cancer cells10.1038/s41388-021-01865-8 ↗
27. VCAM-1 secreted from cancer-associated fibroblasts enhances the growth and invasion of lung cancer cells through AKT and MAPK signaling10.1016/j.canlet.2019.12.039 ↗
28. Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways10.1186/s13046-020-01611-0 ↗
29. Expression levels of cleaved caspase-3 and caspase-3 in tumorigenesis and prognosis of oral tongue squamous cell carcinoma
30. Extracellular vesicles are transferred from melanocytes to keratinocytes after UVA irradiation10.1038/srep27890 ↗
31. Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma10.1038/s41467-022-28801-y ↗
32. Keratin 17 suppresses cell proliferation and epithelial-mesenchymal transition in pancreatic Cancer
33. In search of definitions: cancer-associated fibroblasts and their markers10.1002/ijc.32193 ↗
34. Doxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking10.1021/mp100269f ↗
35. Effective breast cancer therapy based on palmitic acid-loaded PLGA nanoparticles. Biomaterials
36. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee
37. Doxorubicin skin penetration from monoolein-containing propylene glycol formulations10.1016/j.ijpharm.2006.08.021 ↗
38. Effect of the iontophoresis of a chitosan gel on doxorubicin skin penetration and cytotoxicity10.1016/j.jconrel.2008.11.002 ↗
39. Advanced nanocarrier- and microneedle-based transdermal drug delivery strategies for skin diseases treatment10.7150/thno.69999 ↗
40. Site-specific vesicular drug delivery system for skin cancer: a novel approach for targeting10.3390/gels7040218 ↗
41. Advancements in nanoparticle-based treatment approaches for skin cancer therapy10.1186/s12943-022-01708-4 ↗
42. Therapeutic nanoparticles in clinics and under clinical evaluation10.2217/nnm.13.8 ↗
43. Doxil®—the first FDA-approved nano-drug: lessons learned10.1016/j.jconrel.2012.03.020 ↗
44. Control of polymeric nanoparticle size to improve therapeutic delivery10.1016/j.jconrel.2015.10.006 ↗
45. Microfluidic self-assembly of polymeric nanoparticles with tunable compactness for controlled drug delivery10.1016/j.polymer.2013.07.022 ↗
46. Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency10.1016/j.ejpb.2008.01.013 ↗
47. Production of fluconazole-loaded polymeric micelles using membrane and microfluidic dispersion devices
48. Abioye, A.O.; Chi, G.T.; Kola-Mustapha, A.T.; Ruparelia, K.C.; Beresford, K.J.M.; Arroo, R.R.J. Polymer-Drug Nanoconjugate – An Innovative Nanomedicine: Challenges and Recent Advancements in Rational Formulation Design for Effective Delivery of Poorly Soluble Drugs. pp. 38–79.
49. Doxorubicin-loaded polymeric nanoparticles containing ketoester-based block and cholesterol moiety as specific vehicles to fight estrogen-dependent breast cancer10.1186/s12645-023-00176-9 ↗
50. Doxorubicin-loaded star-shaped copolymer PLGA-vitamin E TPGS nanoparticles for lung cancer therapy10.1007/s10856-015-5498-z ↗
51. Dendrimer-doxorubicin conjugates exhibit improved anticancer activity and reduce doxorubicin-induced cardiotoxicity in a murine hepatocellular carcinoma model10.1371/journal.pone.0181944 ↗
52. The roles of tumor- and metastasis-promoting carcinoma-associated fibroblasts in human carcinomas10.1007/s00441-016-2471-1 ↗
53. Role of stromal myofibroblasts in invasive breast cancer: stromal expression of alpha-smooth muscle actin correlates with worse clinical outcome10.1007/s12282-010-0234-5 ↗
54. Modified scar grade: a prognostic indicator in small peripheral lung adenocarcinoma10.1002/cncr.11006 ↗
55. Fuentes-Martínez, N.; García-Pravia, C.; García-Ocaña, M.; Menéndez-Rodríguez, P.; Del Amo, J.; Suárez-Fernández, L.; Galván, J.A.; De los Toyos, J.R.; Barneo, L. Overexpression of proCOL11A1 as a stromal marker of breast cancer. Histol. Histopathol. 2015, 30, 87–93, doi:10.14670/hh-30.87.
56. Organ-, inflammation- and cancer specific transcriptional fingerprints of pancreatic and hepatic stellate cells10.1186/1476-4598-9-88 ↗
57. COL11A1/(pro)collagen 11A1 expression is a remarkable biomarker of human invasive carcinoma-associated stromal cells and carcinoma progression10.1007/s13277-015-3295-4 ↗
58. The application of nanoparticles in cancer immunotherapy: targeting tumor microenvironment
59. SOX10 is as specific as S100 protein in detecting metastases of melanoma in lymph nodes and is recommended for sentinel lymph node assessment10.1016/j.ejca.2020.06.037 ↗
60. SOX10 as an immunohistochemical marker in cancer diagnostics
61. Molecular profiling of cutaneous squamous cell carcinomas and actinic keratoses from organ transplant recipients10.1186/1471-2407-13-58 ↗
62. Keratin 17 in disease pathogenesis: from cancer to dermatoses10.1002/path.5178 ↗
63. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer10.1084/jem.20162024 ↗
64. Human skin permeation enhancement using PLGA nanoparticles is mediated by local pH changes10.3390/pharmaceutics13101608 ↗